KELOWNA, BRITISH COLUMBIA--(Marketwire - March 18, 2008) - Sernova Corp. (TSX VENTURE: SVA) is pleased to announce that the company will be meeting with the United States Food and Drug Administration (FDA) on April 25, 2008 regarding Sertolin, the company's investigational cellular therapy being developed for diabetes treatment. This formal pre-Investigational New Drug (IND) meeting is Sernova's first step in seeking IND approval to initiate clinical trials in humans. The FDA meeting will provide Sernova with the opportunity to present its experimental data on Sertolin, obtain feedback on its pre-clinical data package, and receive the FDA's perspective on its proposed clinical strategy.
